In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision was known. What was not known, until September 2025, was the detailed reasoning behind it.
That changed when the FDA announced a new policy requiring real-time public release of Complete Response Letters, the formal documents the agency sends to drug sponsors when an application cannot be approved. Along with that announcement, the FDA published a backlog of 89 previously withheld letters, including the one sent to Lykos Therapeutics.
At JourneyŌM, we think this kind of transparency is worth paying attention to. Not because the rejection should cause alarm, but because understanding it clearly is more useful than reacting to headlines.
What a Complete Response Letter actually is
A Complete Response Letter (CRL) is not a final rejection. It is a formal, documented list of deficiencies the FDA requires a sponsor to address before the application can be reconsidered. A sponsor can resolve those concerns and resubmit. But the letter carries real weight, and now that CRLs are publicly released in real time, the entire field can see exactly where an application fell short.
That shift matters. Previously, this kind of information stayed largely between the FDA and the sponsor. Now researchers, advocates, investors, and anyone considering psychedelic-assisted support can read the FDA’s reasoning directly. That is useful information, and it changes how future sponsors will approach the agency.
The three concerns the FDA raised
The Lykos CRL identified three distinct areas where the application did not meet the required standard. Each one is worth understanding on its own terms rather than as part of a general narrative about psychedelic medicine.
Safety data gaps and reporting concerns
The FDA raised concerns about how adverse events were captured and reported across trial sites. The issue was not that MDMA caused obvious harms that were covered up. The issue was that the agency lacked sufficient confidence that all safety signals had been fully identified, documented, and disclosed in a consistent way. As a condition of resubmission, the FDA requested an independent data audit.
For a drug seeking federal approval for a serious psychiatric condition, the safety picture needs to be complete. Partial or inconsistently reported data cannot support that standard, regardless of how promising the clinical outcomes appeared.
Durability of benefits
PTSD is a chronic condition, and the FDA’s concern here is straightforward: showing that participants felt significantly better for several months after treatment is not the same as demonstrating that the benefits held over the long term. The submitted trial data did not adequately show that observed improvements were sustained well beyond the treatment window.
For a chronic disorder, durability is not a secondary consideration. It is central to the case for approval, and this gap will need to be addressed substantively in any future submission.
Trial enrollment and generalizability
A high proportion of trial participants had prior experience with MDMA. The FDA raised this as a potential source of bias, because people who already have positive associations with a substance may respond differently from a general patient population with no prior exposure. This affects how well the results generalize, and it is a legitimate methodological concern that future trials will need to address directly in their design.
What this signals for the psychedelic field
The concerns raised in the Lykos CRL reflect something broader than one application’s shortcomings. They outline the evidentiary standard the FDA expects for psychedelic-assisted therapies going forward, and that standard is higher than some corners of the field had anticipated.
The rapid growth of psychedelic medicine research over the past decade generated significant enthusiasm, and some of that enthusiasm outpaced the rigor required to meet regulatory standards. Early trial outcomes were promising. But the FDA’s job is not to approve on the strength of promise. It is to ensure that submitted evidence is complete, auditable, and sufficient to support approval for use in a general patient population with a chronic condition.
MAPS, the advocacy organization behind much of the foundational MDMA research, praised the FDA’s new transparency policy while arguing that the evidentiary goalposts had shifted after the trials were already completed, and that patients living with PTSD were bearing the cost of those delays. That tension reflects a genuine challenge: when regulatory standards evolve mid-process, sponsors face real uncertainty. Both things can be true at once.
What seekers should actually take away from this
If you are exploring psychedelic-assisted support, the MDMA therapy FDA rejection is not a reason to stop your inquiry. It is a reason to be better informed about what is and is not currently established.
Here is the actual landscape as of mid-2026. There are no federally approved psychedelic medicines for psychotherapy in the United States. MDMA-assisted therapy for PTSD did not receive approval. Psilocybin is accessible through state-regulated frameworks in Oregon and Colorado, outside any federal clinical approval context. Ketamine is legally available and widely used, though the evidence base for its long-term efficacy varies by condition and route of administration.
What is available right now is not what the landscape will look like in two or three years. The FDA’s new transparency policy means that the reasoning behind future approvals and rejections will be publicly visible as they happen, which makes it easier to follow the field accurately rather than through filtered reporting.
A few grounded questions worth sitting with as you navigate this: What kind of support are you actually looking for, and is it currently available within a legal, professionally guided framework? Do you understand the difference between state-regulated access and federally approved treatment? Are you working with someone who can help you assess readiness, risk, and realistic expectations for what a guided experience can and cannot do?
The durability question connects directly to integration
One of the more underexamined aspects of the Lykos CRL is what the durability concern actually points to. The FDA wanted evidence that benefits lasted. That is a regulatory standard with specific technical requirements. But it also reflects something that experienced guides and practitioners have understood for a long time: the experience itself is not the endpoint.
What happens in the weeks and months after a psychedelic experience often determines how much of it translates into lasting change in a person’s life. Insight without support tends to fade. Emotional openings that are not followed by structured integration can leave people disoriented rather than genuinely shifted. The field’s regulatory challenges and the practical needs of individual seekers are pointing toward the same gap from different directions.
Integration is not a supplementary service. It is part of what makes psychedelic-assisted work meaningful and sustainable over time, and it is one of the areas where professional guidance makes the most measurable difference.
What this means going forward
The MDMA therapy FDA rejection does not close the door on this area of research. It defines more clearly what a successful resubmission will need to look like: an independent safety data audit, stronger evidence of long-term durability, and trial designs that enroll populations more representative of the general patient base. Those are achievable standards, and there are organizations actively working toward them.
The FDA’s new transparency policy also changes the environment going forward. Every sponsor in the psychedelic space now knows that their CRL, if they receive one, will be public immediately. That raises the stakes for methodological rigor before submission, which is ultimately better for the field and for the people it is trying to serve.
For seekers, the clearest takeaway is this: the regulatory picture is evolving, the available options are more limited than media coverage sometimes suggests, and working with someone who can help you understand both the possibilities and the limits is more valuable now than it has ever been.